Silence Therapeutics: Divesiran Targets High-Burden PV

Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...
The Henderson News

To Your Good Health: Symptoms, not numbers, are the main drivers for a phlebotomy

My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a ...

Dear Doctor: Do omega-3 fatty acids thin your blood?

DEAR DR. ROACH: Do omega-3 fatty acids thin your blood, and can you still take them while taking one low-dose aspirin a day? ...

Quebec becomes the first province to publicly reimburse Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anemia

CNW/ - GSK Canada is pleased to announce that Ojjaara (momelotinib) will now be reimbursed by Régie de l'assurance maladie du ...

Dr. Roach: Symptoms, not numbers, are the main drivers for a phlebotomy

Dear Dr. Roach: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was ...
The Vindicator

Symptoms are main drivers for a phlebotomy

My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his HCT was high. My ...
The Bakersfield Californian

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO ...
Medscape

Weight-Loss Drugs for Polycythemia Vera?

HOUSTON — A retrospective study presented at the Society of Hematologic Oncology (SOHO) 2025 suggested that glucagon-like peptide-1 receptor agonists (GLP-1s) such as semaglutide (Ozempic/Wegovy) — ...